Moderna（MRNA）周三夜盘股价大幅上涨5.98%，成为生物科技板块中的领涨个股。
消息面上，Moderna与默沙东（MSD）联合宣布了其个体化mRNA癌症疫苗intismeran autogene（V940）的2b期临床试验5年随访数据。结果显示，该疫苗与Keytruda联合疗法在高风险黑色素瘤患者中，将复发或死亡风险显著降低49%。这一积极数据进一步验证了mRNA技术在肿瘤治疗领域的潜力，美国FDA和欧洲EMA已分别授予该疗法突破性疗法和PRIME资格认定。
目前，该联合疗法共有8项2/3期临床试验正在进行中，覆盖黑色素瘤、非小细胞肺癌、膀胱癌和肾细胞癌等多种适应症。分析人士认为，这一进展不仅巩固了Moderna在mRNA治疗领域的领先地位，也为公司拓展肿瘤免疫治疗市场奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.